SUMMARY

The Cognigenics approach has four key strengths:

  1. 1. Our straightforward design employs a simple mechanism of action which requires only a single point of contact in cells.
    2. CRISPR’s precise vector targeting to neurons produces positive results without any known side effects.
    3. Our design approach is extensively supported by a large body of neuroscience experiments and validated in the laboratory.
    4. The opportunity to achieve a solution using industry-standard CRISPR editing tools promises significantly lower R&D costs than custom drug development, and allows the company to leverage billions of dollars in ongoing global CRISPR R&D.

The Cognigenics approach has four key strengths:

  1. 1. Our straightforward design employs a simple mechanism of action which requires only a single point of contact in cells.
    2. CRISPR’s precise vector targeting to neurons produces positive results without any known side effects.
    3. Our design approach is extensively supported by a large body of neuroscience experiments and validated in the laboratory.
    4. The opportunity to achieve a solution using industry-standard CRISPR editing tools promises significantly lower R&D costs than custom drug development, and allows the company to leverage billions of dollars in ongoing global CRISPR R&D.

PROGRAM

The company began its preclinical research experiments in 2020. We expect to start clinical trials in 2023 and begin customer shipments in 2025.

Phase 1 :  Safety

Determine safety and dosage in 20-50 healthy adult volunteers for COG-101, an RNA therapy anti-depressant. Monitor subjects to learn more about how the therapy works in the body and the effects associated with increased dosage. Gain early information about efficacy and how best to administer the treatment to limit risks and maximize benefits. Time frame: 2023

Phase 2 :  Efficacy

Measure the RNA therapy’s efficacy in relieving depression symptoms in a group of several hundred patients. Closely monitor subjects to identify any side effects. Time frame: 2024

Phase 3 :  Efficacy and adverse reactions

Phase 3 :
Efficacy and adverse reactions

Measure the RNA therapy’s efficacy in relieving depression symptoms in a group of 300 to 3000 patients. Closely monitor subjects to identify any side effects. Time frame: 2025